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Objective: Treating cancer cells with depsipeptide, a novel antitumor agent
currently in a phase II clinical trial, causes potent upregulation of p21/WAF1
expression and cell arrest at G1 and G2 checkpoints. p21/WAF1 upregulation,
however, impedes the ability of depsipeptide to induce significant apoptosis.
This study was designed to determine whether flavopiridol, a synthetic cyclin-
dependent kinase inhibitor known to inhibit p21 expression in tumor cells, could
enhance depsipeptide-mediated apoptosis in cultured lung and esophageal can-
cer cells.
Methods: Lung or esophageal cancer cells were exposed to depsipeptide, flavopiri-
dol, or a combination of depsipeptide and flavopiridol. Cytotoxicity and apoptosis
were quantitated by means of (4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium
bromide and terminal deoxynucleotidyltransferase-mediated dUTP nick end label-
ing–based assays, respectively. Cytosolic cytochrome c levels, caspase 9 activity,
mitochondrial membrane depolarization, and dependence of apoptosis on caspase 9
in treated cells were studied to determine the role of the mitochondria in mediating
apoptosis induced by this drug combination.
Results: Flavopiridol completely abolished depsipeptide-mediated dose-depen-
dent upregulation of p21/WAF1 expression. Combining flavopiridol with dep-
sipeptide resulted in a 3- to 8-fold reduction of depsipeptide inhibitory concen-
tration of 50% values that was closely paralleled by synergistic enhancement of
apoptosis (4- to 10-fold higher than levels of cell death induced by either drug
alone) in all cancer cell lines. The essential role of mitochondria in mediating
cell death was indicated by robust translocation of cytochrome c from the
mitochondria into the cytosol, 2.5- to 5-fold activation of caspase 9, severe
disruption of mitochondrial inner membrane potential, and complete inhibition
of apoptosis by the selective caspase 9 inhibitor. More important, this drug
combination was not toxic to primary normal epithelial cells derived from the
airway or skin.
Conclusion: The depsipeptide plus flavopiridol combination exhibits powerful
and selective cytocidal activity against cancer but not normal cells. Apoptosis
induced by this combination is mediated by the mitochondria-dependent death
pathway.
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Locally advanced or metastatic non–small celllung cancer (NSCLC) and esophageal can-cer (EsC) are generally refractory to currentstate-of-the-art multimodality therapies. In-deed, there has been little progress in thetreatment outcomes for patients with meta-
static NSCLC.1 The disappointing results of current therapy
for advanced lung cancer or EsC in conjunction with in-
creasing appreciation of the molecular basis of carcinogen-
esis provide the impetus for ongoing efforts to develop
novel and potentially more effective targeted molecular
therapeutic strategies for cancers of the aerodigestive tract.
Depsipeptide, a bicyclic polypeptide isolated from the
fermentation broth of Chromobacterium violaceum, belongs
to a new class of antitumor agents known as histone
deacetylase (HDAC) inhibitors. This compound exhibited
cytotoxicity against a wide range of cancers in preclinical
studies,2 and it is currently in a phase II evaluation at the
National Cancer Institute. Depsipeptide, similar to other
HDAC inhibitors, mediates powerful cell-cycle arrest at
G0/G1 and G2/M checkpoints.3-5 This is attributable in part
to its ability to upregulate the expression of the cyclin-
dependent kinase (cdk) inhibitor p21/WAF1. This drug-
induced p21 upregulation, although effective in causing
cell-cycle arrest, has been shown to impede the ability of
depsipeptide and other HDAC inhibitors to mediate pro-
grammed cell death.5 Abrogation of depsipeptide-mediated
p21 upregulation was shown to enhance its ability to induce
apoptosis.5
Flavopiridol is a synthetic cdk inhibitor that is currently
in early clinical development. We have previously demon-
strated that flavopiridol mediates apoptosis in EsC cells.6
Moreover, flavopiridol has been shown to transciptionally
inhibit p21/WAF1 expression in U937 leukemia cells in
more recent studies.7,8 We therefore hypothesized that fla-
vopiridol might abrogate depsipeptide-mediated upregula-
tion of p21/WAF1 expression, thereby enhancing apoptosis
in NSCLC and EsC cells.
Materials and Methods
Cells and Reagents
The NSCLC cells H322 and H460 and the EsC cells TE-12 and
TE-13 were maintained in RPMI-1640 culture medium supple-
mented with glutamine (2 mmol/L), penicillin (100 U/mL), strep-
tomycin (100 g/mL), and 10% fetal calf serum (RPMI complete).
Primary normal human bronchial epithelial cells and normal hu-
man epidermal keratinocytes were purchased from Clonetics Corp
(Walkerville, Md) and grown in serum-free culture media as per
the vendor’s instructions. Depsipeptide and flavopiridol (obtained
from the Cancer Treatment and Evaluation Program, National
Cancer Institute, Bethesda, Md) were dissolved in dimethyl sul-
foxide as 250 mg/mL and 2 mmol/L stocks, respectively, and
stored at 20°C. The caspase 9 functional assay kit and the
cytochrome c enzyme-linked immunosorbent assay (ELISA) kit
were purchased from R&D Systems (Minneapolis, Minn). JC-1
dye and (4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) were obtained from Molecular Probes (Eugene, Ore)
and Sigma (St Louis, Mo), respectively.
Cytotoxic Assays
Cells were seeded into 96-well microtiter plates and incubated
overnight before drug treatment. For the dose-dependent cytotox-
icity assay, cells were treated with depsipeptide (1-50 ng/mL) for
6 hours. After drug removal and one wash with drug-free RPMI
complete medium, cells were further treated with flavopiridol (50
or 100 nmol/L) for 66 hours. Viable cells were quantitated by
using the MTT assay. For time-course experiments, cells were
similarly treated with depsipeptide, flavopiridol, or a combination
of depsipeptide and flavopiridol, and cell viability was determined
at 24, 48, and 72 hours after the onset of drug exposure. The
sensitivity of tumor cells to depsipeptide (after depsipeptide treat-
ment alone or in combination with flavopiridol) was determined by
estimating the depsipeptide doses that induced 50% growth inhi-
bition from the dose-response curves (appropriate corrections were
made to account for the mild growth-inhibitory effect of flavopiri-
dol when calculating depsipeptide doses that induced 50% growth
inhibition of cells treated with the drug combination). Drug-in-
duced apoptosis was assessed by using a terminal deoxynucleoti-
dytransferase-mediated dUTP nick end labeling (TUNEL)–based
Apo-BrdU assay with a commercially available kit (Pharmingen,
Torrence, Calif).
Quantitation of p21/WAF1
Cells were harvested 24 hours after the onset of depsipeptide,
flavopiridol, or depsipeptide plus flavopiridol treatments, and p21/
WAF1 levels were measured by means of ELISA (Oncogene
Science, Boston, Mass), normalized for protein content of cell
lysates, and expressed as units per milligram of cellular protein.
Figure 1. Abrogation of depsipeptide (DP)–mediated upregulation
of p21 protein expression in NSCLC or EsC cells by flavopiridol
(FLA). Values are means  SD of 4 independent experiments.
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Measurements of Caspase 9 Activity and Cytosolic
Cytochrome c
Cytosolic extracts were prepared from whole-cell lysates by using
commercially available reagents and protocols (Clontech, Palo
Alto, Calif). Caspase 9 activity and cytosolic cytochrome c levels
in cells treated with depsipeptide, flavopiridol, or depsipeptide plus
flavopiridol were determined by using a functional assay kit and by
an using ELISA, respectively. Cytochrome c and caspase 9 levels
were corrected for protein content of the samples and expressed as
fold increases over those of untreated control samples.
Determination of Mitochondrial Inner Membrane
Potential
Cells were harvested by means of trypsinization 36 hours after the
onset of drug treatment and washed once with drug-free culture
medium. The cells were then incubated with JC-1 for 30 minutes
at 37°C. Cells were washed twice with phosphate-buffered saline
solution and immediately analyzed by means of flow cytometry.
Loss of mitochondrial inner membrane potential was indicated by
reduction of JC-1 red fluorescence.
Statistical Analysis
Data are presented as means  SD. Statistical analysis, when
indicated, was performed by using the Student t test.
Results
Abrogation of Depsipeptide-Mediated Upregulation of
p21 by Flavopiridol
Exposure of H460 and H322 NSCLC cells or TE-12 and
TE-13 EsC cells to depsipeptide for 6 hours resulted in a
dose-dependent increase of p21/WAF1 expression ranging
from 6- to 10-fold of respective baseline levels. Flavopiridol
treatment (150 nmol/L), although not affecting the basal
Figure 2A. Dose-dependent enhancement of depsipeptide (DP)–mediated cytotoxicity of the NSCLC cells H460 and
H322 and the EsC cells TE-12 and TE-13 by flavopiridol (FLA; 50-100 nmol/L). The sensitivity of tumor cells to
depsipeptide is indicated by depsipeptide doses that induced 50% growth inhibition (IC50; in nanograms per
milliliter). Values shown are means  SD of 4 independent experiments.
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p21/WAF1 expression, completely abrogated the depsipep-
tide-mediated upregulation of this cdk inhibitor (Figure 1).
Synergistic Cytotoxic Effect of the Depsipeptide Plus
Flavopiridol Combination in Cancer Cell Lines but
not Primary Normal Cells
Exposure of tumor cells to depsipeptide for 6 hours resulted
in a dose-dependent inhibition of cell growth. Subsequent
treatment of depsipeptide-exposed tumor cells with fla-
vopiridol (50-100 nmol/L) led to drastic dose-dependent
inhibition of cell proliferation that greatly exceeded the mild
growth-inhibitory effect of flavopiridol noted in tumor cells
treated with this agent alone (Figure 2A). The synergistic
cytotoxic effect of this drug combination was most pro-
nounced in H322, TE-12, and TE-13 cells. Time-course
experiments indicated that although tumor cells treated with
either depsipeptide alone or flavopiridol alone exhibited
varying degrees of growth retardation (Figure 2B), active
cell death occurred in those treated with the drug combina-
tion (evidenced by rapid reduction of viable cells to levels
well below those present at the beginning of the experi-
ment). In TE-12 or TE-13 cells the cytotoxic effect of this
drug combination was so powerful that all tumor cells were
eliminated by 48 hours after the onset of drug exposure.
To determine whether the depsipeptide plus flavopiridol
combination would be toxic to normal cells, similar exper-
iments were conducted with primary normal cells (human
epidermal keratinocytes or bronchial epithelial cells) grown
Figure 2B. Time course of the synergistic cytocidal effect of the depsipeptide (DP) plus flavopiridol (FLA) drug
combination in H460, H322, TE-12, and TE-13 cells. Although individual depsipeptide or flavopiridol treatment
resulted in retardation of cell proliferation, significant cell death was observed in cells treated with the drug
combination. Cell viability was quantitated by means of MTT assay and expressed as an optical density (OD) at
570 nm. Values shown are means  SD of 3 independent experiments.
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to confluence in vitro. Quite remarkably, this drug combi-
nation, although being extremely powerful in killing cancer
cells, demonstrated only marginal cytotoxic effects toward
normal cells (Figure 2C).
Massive induction of apoptosis was noted in all tumor
cells treated with this drug combination by using the
TUNEL–based Apo-BrdU assay to detect DNA fragmenta-
tion. For instance, although 15% and 20% of apoptotic cells
were observed after depsipeptide or flavopiridol treatment
in TE-12 or TE-13 esophageal cells, up to 90% of these cells
were apoptotic within 48 hours after exposure to the se-
quential depsipeptide plus flavopiridol combination, a clear
synergistic combination effect (Figure 3). Similar observa-
tions were made when the NSCLC cells H460 or H322 were
treated with depsipeptide, flavopiridol, or the depsipeptide
plus flavopiridol combination, albeit at a slightly lower
magnitude of apoptosis (Figure 3).
The Depsipeptide Plus Flavopiridol Combination
Induced Apoptosis Through the Mitochondria-
Dependent Pathway
Expression of Bax (proapoptosis) and Bcl2 (antiapoptosis)
proteins in tumor cells (H322 and TE-12 cells) treated with
depsipeptide, flavopiridol, or the depsipeptide plus fla-
vopiridol combination was determined by Western blotting,
and their relative levels were quantitated by densitometry.
In H322 cells depsipeptide plus flavopiridol treatment was
associated with a strong upregulation of Bax and unchanged
Bcl2 levels. On the other hand, the Bax level remained
unchanged, whereas the Bcl2 level decreased after dep-
sipeptide plus flavopiridol in TE-12 cells. The net result in
both cases was a profound increase in Bax/Bcl2 ratios that
favors the induction of apoptosis9 in cells treated with the
depsipeptide plus flavopiridol combination (Figure 4).
In conjunction with alterations of Bax and Bcl2 levels
was the massive release of cytochrome c from the mito-
chondrial intermembrane space into the cytosol in NSCLC
and EsC cells treated with the depsipeptide plus flavopiridol
combination (Figure 5). Once released from mitochondria
into the cytoplasm, cytochrome c combines with Apaf-1,
adenosine triphosphate, and procaspase 9 to form the apo-
tosome, which catalytically activates caspase 9 and thus
initiates caspase-dependent programmed cell death.10 Al-
though cancer cells treated with either depsipeptide or fla-
vopiridol treatment alone had minimal effect on caspase 9
activity, those treated with the depsipeptide plus flavopiri-
dol combination exhibited a 2.8- to 5-fold increase in the
levels of caspase 9 activity starting around 24 hours (H322,
TE-12, and TE-13) to 36 hours (H460) after the onset of
drug exposure (Figure 6). Moreover, depsipeptide plus fla-
vopiridol treatment of cancer cells led to profound mito-
chondrial damage indicated by massive loss of mitochon-
dria inner membrane potentials (depolarization), as detected
by means of JC-1 staining and flow cytometry (Figure 7).
Cells with depolarized mitochondria exhibited reduction of
red but not green fluorescence and were gated to the right
Figure 2C. Lack of significant cytotoxic effect of depsipeptide,
flavopiridol (FLA), or the depsipeptide plus flavopiridol combina-
tion in normal cells. Values shown are means  SD of 3 inde-
pendent experiments.
Figure 3. Profound and synergistic induction of apoptosis in
NSCLC or EsC cells by the depsipeptide (DP) plus flavopiridol
(FLA) drug combination. Values shown are means  SD of 3
independent experiments.
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lower quadrants of the dot plots. The robust apoptosis
mediated by the depsipeptide plus flavopiridol combination
was almost completely abrogated by the selective caspase 9
inhibitor, conclusively affirming the notion that mitochon-
dria-dependent caspase 9 activation was essential for dep-
sipeptide plus flavopiridol–mediated apoptosis (Figure 8).
Discussion
Depsipeptide is currently under phase II evaluation in pa-
tients with refractory lung cancers at the National Cancer
Institute. The pharmacokinetic and toxicity profiles of dep-
sipeptide derived from the phase I trial have been recently
reported.11 Depsipeptide has been shown to deplete multiple
growth signaling–related proteins (mutant p53, erbB1,
erbB2, and Raf-1), as well as to alter the expression of
several cell-cycle proteins (upregulation of p21/WAF1 and
cyclin E, downregulation of cyclin A) in lung cancer cells,
all of which might contribute to the antiproliferative effect
of this agent.12 Modest induction of apoptosis was observed
after depsipeptide treatment but only after 24 hours of drug
exposure.12 Upregulation of p21/WAF1 is a constant feature
of HDAC inhibitors, including depsipeptide. Although re-
sponsible for cell arrest at G1 and G2 checkpoints, it actu-
Figure 5. Significant accumulation of cytochrome c in the cytosolic
fraction of the cell lysates was noted in NSCLC H460 and H322 cells
or EsC TE-12 and TE-13 cells after treatment with the depsipeptide
plus flavopiridol drug combination. Cells were harvested at 20 hours
(H322, TE-12, and TE-13 cells) or 40 hours (H460) after the onset of
drug exposure; cytosolic cytochrome c levels were measured by
ELISA. Representative data from a series of 3 independent experi-
ments with similar results are shown.
Figure 4. Western blot analysis of drug-induced alteration of Bax and Bcl2 levels in H322 or TE-12 cells at 18 hours after
the onset of drug exposure. The relative levels of Bax and Bcl2 were quantitated by densitometry. This finding was
reproduced in another independent experiment. DP, Depsipeptide; FLA, flavopiridol.
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ally reduces cytotoxicity and apoptosis mediated by these
agents, as suggested by many lines of evidence: p21/
cells were more susceptible to apoptosis induced by HDAC
inhibitors than their p21/ parental cells,3,5 interference
with p21/WAF1 upregulation by a p21 antisense construct
enhances the cytocidal effect of HDAC inhibitors,8 and cells
lacking the usual p21/WAF1 upregulation response are very
sensitive to the cytotoxic effect of HDAC inhibitors.5 The
logical approach one would take to augment the therapeutic
efficacy of depsipeptide or other HDAC inhibitors in addi-
tion to using higher doses or longer durations of drug
exposure (associated with higher propensity for side effects)
is to inhibit drug-induced p21/WAF1 upregulation by using
either an approved drug or an experimental agent that is
currently under clinical development. The resulting combi-
nation should also be clinically applicable and safe. Fla-
vopiridol, a potent cdk inhibitor, appeared to fit this role
very well. On the basis of its favorable antitumor activity
observed in preclinical studies, flavopiridol has been used in
clinical trials to treat solid tumors, either as single agent or
in combination with conventional chemotherapeutics.13,14
The pharmacokinetic and toxicity profiles of this agent have
been well described in phase I and II clinical trials.13,14 As
a single agent, flavopiridol was been reported to modulate
the expression of Bax, Bcl2, or both and to induce apoptosis
of cancer cells in vitro.6,14,15 Of particular relevance to our
study is the finding that flavopiridol transcriptionally inhib-
ited p21/WAF1 upregulation mediated by the protein kinase
C activator phorbol 12-myristate 13-acetate in U937 leuke-
mia cells.7
Our data clearly demonstrate the superior cytotoxic ef-
fect of the depsipeptide plus flavopiridol combination to that
of either depsipeptide or flavopiridol alone on NSCLC and
EsC cells in vitro. The selections of drug treatment sched-
ules (6 hours of depsipeptide and 66 hours of flavopiridol)
were based on those used in phase I clinical trials of each
Figure 6. The time course of caspase 9 activation in cancer cell lines after depsipeptide (DP), flavopiridol (FLA),
or depsipeptide plus flavopiridol treatments. Relative levels of caspase 9 activities are shown as folds of levels
in untreated control cells.
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respective drug.11,13 Moreover, plasma drug concentrations
(depsipeptide, 25-50 ng/mL; flavopiridol, 100-150 nmol/L)
similar to those required to yield synergistic cytotoxic ef-
fects in vitro would be clinically achievable according to
pharmacokinetic data obtained in these phase I clinical
trials.11,13 Another important and clinically relevant finding
of our study was the lack of cytotoxicity with this drug
combination in primary normal cells grown to confluence in
vitro. Normal human bronchial epithelial cells and skin
keratinocytes were chosen to represent normal counterparts
of NSCLC and EsC cells, respectively. Although depsipep-
tide or flavopiridol, as single agents, mediate varying de-
grees of apoptosis in cancer cells derived from solid tu-
mors,6,11,15,16 the ability of the drug combination to induce
massive apoptosis through a mitochondria-dependent path-
way in NSCLC or EsC cells deserves in-depth evaluation.
Mitochondria, although being an indispensable life-sup-
porting component of all eukaryotes, play a crucial role in
inducing apoptosis of the very cells they are meant to
sustain when appropriately activated by intracellular or ex-
tracellular death signals (Figure 9). Extracellular death sig-
nals (FasL, tumor necrosis factor, or tumor necrosis factor
receptor apoptosis–inducing ligand) bind to their respective
receptors to activate caspase 8, leading to direct or indirect
(through activation of Bid, the connector that links extra-
cellular death signals to the mitochondria-dependent death
pathway) activation of caspase 3, leading to apoptosis.17
Intracellular death signals, such as those initiated with che-
motherapeutics or other cytotoxic agents, activate the mito-
chondria by modulating the function, expression, or both of
proapoptotic proteins (eg, Bid, Bax, and Bak), antiapoptotic
proteins (eg, Bcl2 and BclXL), or both.18 Activated pro-
apoptotic proteins converge on the mitochondrial outer
membrane to form conducting channels through homo-
oligomerization or hetero-oligomerization, allowing cyto-
chrome c that resides in the intermembrane matrix to trans-
Figure 7. Perturbation of mitochondrial function after drug exposure indicated by the loss of mitochondrial inner
membrane potential, as assessed by means of JC-1 staining and flow cytometry. Cells with loss of mitochondrial
inner membrane potential are sorted to the right lower quadrant of the dot plots. Representative data from a series
of 3 independent experiments with similar results are shown.
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locate to the cytoplasm.19 Cytosolic cytochrome c, in turn,
combines with adenosine triphosphate, procaspase 9, and
Apaf-1 to form a complex known as the apoptosome, which
activates caspase 9 and, subsequently, caspase 3.10 Bcl2 and
BclXL can inhibit the initiation of apoptosis by interfering
with the interaction of activated Bax, Bak, and Bid with
mitochondria at many levels and thus preventing cyto-
chrome c release.20 The depsipeptide plus flavopiridol com-
bination induces mitochondria-dependent apoptosis in tu-
mor cells by targeting the upstream components of this
death pathway (ie, the Bax and Bcl2 proteins). Indeed, cells
treated with this drug combination exhibit alterations of Bax
and Bcl2 levels associated with the highest Bax/Bcl2 ratios
that set the appropriate condition for mitochondrial activa-
tion, leading to robust translocation of cytochrome c into the
cytosol compartment, caspase 9 activation, and apoptosis.
The mechanism by which depsipeptide in combination with
flavopiridol alters Bax and Bcl2 expression is unclear. This
and other issues related to the effects of depsipeptide plus
flavopiridol on other components upstream and downstream
of the mitochondria in this death-signaling pathway are
topics of ongoing investigation in our laboratory.
Although not conclusively demonstrated in our present
experiments, abrogation of depsipeptide-mediated p21/
WAF1 upregulation by flavopiridol in all likelihood con-
tributes to the profound induction of apoptosis mediated by
the sequential depsipeptide plus flavopiridol combination.
p21/WAF1 has been demonstrated to bind to procaspase 3
and inhibit its proteolytic activation.21 Caspase 3 activation,
however, is not an initiating event because it occurs down-
stream in the caspase-dependent apoptosis cascade. Never-
theless, activated caspase 3 can amplify the apoptosis effect
of the upstream death signals by activating caspase 8
through a positive feedback loop.22 The complex interaction,
Figure 8. Inhibition of depsipeptide (DP) plus flavopiridol (FLA)–mediated induction of apoptosis in NSCLC cells or
EsC cells by the selective caspase 9 inhibitor (20 mol/L added to the culture media just before flavopiridol
exposure). Representative data from a series of 3 independent experiments with similar results are shown.
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connection, or both between p21/WAF1 downregulation and
alteration of the Bax/Bcl2 ratio observed in cells treated with
depsipeptide plus flavopiridol remains to be elucidated.
Although the mechanisms by which sequential depsipep-
tide plus flavopiridol treatment mediates apoptosis in cancer
cells have not been fully elucidated, our data clearly indicate
that this novel drug combination exhibits potent cytotoxicity
preferentially in malignant and not in normal cells. Preclin-
ical animal studies with human xenografts are being per-
formed to confirm this apparent salutary effect and to eval-
uate the safety of this drug combination in vivo. These
compelling data provide the rationale for further clinical
development of this drug combination to treat refractory
malignant disease.
We thank Arnold Mixon and Shawn Farid for performing flow
cytometric studies.
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Discussion
Dr Stephen G. Swisher (Houston, Tex). Did you use cyclo-
sporine A or bongkrekic acid to try and block the mitochondria,
and did that block your apoptosis?
Dr Nguyen. No, I have not tried that. The interesting thing is,
when I looked at the time course of cytochrome c release and
activation of caspase 9 and the mitochondrial depolarization, there
was a dissociation. The depolarization occurred quite late. It hap-
pened around 36 hours after onset of drug treatment, whereas
cytochrome c release was detected around 18 to 20 hours and
activation of caspase 9 was noted around 24 hours after drug
exposure. Therefore, I have not tried these blocking agents, but I
think membrane depolarization is a product of caspase activation
rather than the primary event.
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